AstraZeneca Begins Nationwide Home Delivery of FluMist Nasal Flu Vaccine

AstraZeneca on Friday introduced “FluMist Home,” an online service that ships its FluMist nasal spray influenza vaccine directly to consumers in 34 U.S. states. The product, first approved in 2003, can now be self-administered by adults aged 18–49 or given by a caregiver to children aged 2–17, following Food and Drug Administration clearance for at-home use granted in September 2024. Customers complete a medical screening on FluMist.com; a licensed health-care provider reviews eligibility before prescriptions are filled and dispatched in temperature-controlled packaging. Most insurance plans cover the vaccine, while AstraZeneca estimates a sub-$10 shipping fee for a four-dose order. The company aims to expand availability to the entire contiguous United States as state pharmacy rules allow. AstraZeneca says the needle-free, direct-to-consumer option is intended to remove barriers such as clinic visits and fear of injections, and thereby lift U.S. flu immunisation rates. The launch comes after the Centers for Disease Control and Prevention classified the 2024-25 flu season as the most severe since 2009, recording an estimated 610,000 hospitalisations and 27,000 deaths.